Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:AUPH's Cash-to-Debt is ranked higher than
94% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:AUPH: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AUPH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11  Med: 137.78 Max: No Debt
Current: No Debt
Equity-to-Asset 0.86
NAS:AUPH's Equity-to-Asset is ranked higher than
81% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:AUPH: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AUPH' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.8  Med: 0.69 Max: 0.95
Current: 0.86
-0.8
0.95
Interest Coverage No Debt
NAS:AUPH's Interest Coverage is ranked higher than
92% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:AUPH: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:AUPH' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 7.70
Beneish M-Score: 0.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -8215.46
NAS:AUPH's Operating Margin % is ranked lower than
91% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:AUPH: -8215.46 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AUPH' s Operating Margin % Range Over the Past 10 Years
Min: -13187.28  Med: -555.46 Max: -67.41
Current: -8215.46
-13187.28
-67.41
Net Margin % -16721.42
NAS:AUPH's Net Margin % is ranked lower than
94% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:AUPH: -16721.42 )
Ranked among companies with meaningful Net Margin % only.
NAS:AUPH' s Net Margin % Range Over the Past 10 Years
Min: -16721.42  Med: -354.16 Max: -111.75
Current: -16721.42
-16721.42
-111.75
ROE % -82.38
NAS:AUPH's ROE % is ranked lower than
70% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:AUPH: -82.38 )
Ranked among companies with meaningful ROE % only.
NAS:AUPH' s ROE % Range Over the Past 10 Years
Min: -431.65  Med: -83.33 Max: -38.02
Current: -82.38
-431.65
-38.02
ROA % -64.18
NAS:AUPH's ROA % is ranked lower than
72% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:AUPH: -64.18 )
Ranked among companies with meaningful ROA % only.
NAS:AUPH' s ROA % Range Over the Past 10 Years
Min: -102.67  Med: -49.43 Max: -19.69
Current: -64.18
-102.67
-19.69
ROC (Joel Greenblatt) % -124290.86
NAS:AUPH's ROC (Joel Greenblatt) % is ranked lower than
97% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:AUPH: -124290.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AUPH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -124290.86  Med: -1641.39 Max: -255.41
Current: -124290.86
-124290.86
-255.41
3-Year Revenue Growth Rate -65.00
NAS:AUPH's 3-Year Revenue Growth Rate is ranked lower than
87% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:AUPH: -65.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:AUPH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -82  Med: -26.5 Max: 60.5
Current: -65
-82
60.5
3-Year EBITDA Growth Rate -5.20
NAS:AUPH's 3-Year EBITDA Growth Rate is ranked lower than
59% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NAS:AUPH: -5.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:AUPH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -63.3  Med: -4.5 Max: 20.4
Current: -5.2
-63.3
20.4
3-Year EPS without NRI Growth Rate 25.40
NAS:AUPH's 3-Year EPS without NRI Growth Rate is ranked higher than
77% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NAS:AUPH: 25.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AUPH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -62  Med: -9.35 Max: 251.3
Current: 25.4
-62
251.3
GuruFocus has detected 4 Warning Signs with Aurinia Pharmaceuticals Inc NAS:AUPH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AUPH's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

AUPH Guru Trades in Q3 2016

Jim Simons 85,100 sh (+107.06%)
» More
Q4 2016

AUPH Guru Trades in Q4 2016

Jim Simons Sold Out
» More
Q1 2017

AUPH Guru Trades in Q1 2017

Jim Simons 105,700 sh (New)
» More
Q2 2017

AUPH Guru Trades in Q2 2017

Jim Simons 71,001 sh (-32.83%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:AUPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 3741
Compare:OSL:NANO, SZSE:002566, OSTO:PROB, NAS:BCRX, SHSE:603538, NAS:PDLI, SHSE:600556, NAS:ATRA, ROCO:4157, SHSE:600866, NAS:PGNX, NAS:CMTA, SZSE:300404, TSE:2160, NAS:JNCE, SZSE:002868, NAS:VYGR, LSE:HZD, XSWX:MOLN, XBRU:CYAD » details
Traded in other countries:AUP.Canada, IKAP.Germany,
Headquarter Location:Canada
Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The Company is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.

Aurinia Pharmaceuticals Inc was formed in April 27, 2009. The Company is a clinical stage pharmaceutical company. The Company's business is the development of a therapeutic drug to treat autoimmune diseases, in particular Lupus Nephritis, and for the prevention of graft rejection in solid organ transplant patients. Its focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of lupus nephritis. Voclosporin belongs to a class of drugs called Calcineurin Inhibitors, the cornerstone of therapy for the prevention of organ transplant rejection. The Company's operations comprise a single reporting segment engaged in the research, development and commercialization of therapeutic drugs. Its geographical areas include: Canada, United States, China and Korea.

Ratios

vs
industry
vs
history
PB Ratio 2.81
AUPH's PB Ratio is ranked higher than
68% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. AUPH: 2.81 )
Ranked among companies with meaningful PB Ratio only.
AUPH' s PB Ratio Range Over the Past 10 Years
Min: 0.77  Med: 3.5 Max: 9.22
Current: 2.81
0.77
9.22
PS Ratio 990.71
AUPH's PS Ratio is ranked lower than
96% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. AUPH: 990.71 )
Ranked among companies with meaningful PS Ratio only.
AUPH' s PS Ratio Range Over the Past 10 Years
Min: 0.86  Med: 30.96 Max: 2266
Current: 990.71
0.86
2266
EV-to-EBIT -8.37
AUPH's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. AUPH: -8.37 )
Ranked among companies with meaningful EV-to-EBIT only.
AUPH' s EV-to-EBIT Range Over the Past 10 Years
Min: -38.4  Med: -3.6 Max: 5.1
Current: -8.37
-38.4
5.1
EV-to-EBITDA -8.75
AUPH's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. AUPH: -8.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
AUPH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -216.9  Med: -3.6 Max: 298.2
Current: -8.75
-216.9
298.2
EV-to-Revenue 686.94
AUPH's EV-to-Revenue is ranked lower than
92% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. AUPH: 686.94 )
Ranked among companies with meaningful EV-to-Revenue only.
AUPH' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.7  Med: 25.5 Max: 1924.8
Current: 686.94
-0.7
1924.8
Current Ratio 53.07
AUPH's Current Ratio is ranked higher than
99% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. AUPH: 53.07 )
Ranked among companies with meaningful Current Ratio only.
AUPH' s Current Ratio Range Over the Past 10 Years
Min: 0.06  Med: 5.25 Max: 53.07
Current: 53.07
0.06
53.07
Quick Ratio 53.07
AUPH's Quick Ratio is ranked higher than
99% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. AUPH: 53.07 )
Ranked among companies with meaningful Quick Ratio only.
AUPH' s Quick Ratio Range Over the Past 10 Years
Min: 0.06  Med: 5.22 Max: 53.07
Current: 53.07
0.06
53.07
Days Sales Outstanding 247.16
AUPH's Days Sales Outstanding is ranked lower than
93% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. AUPH: 247.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
AUPH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 10.91  Med: 55.55 Max: 247.16
Current: 247.16
10.91
247.16

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -62.20
AUPH's 3-Year Average Share Buyback Ratio is ranked lower than
87% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. AUPH: -62.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AUPH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -109.1  Med: -16.8 Max: -4.1
Current: -62.2
-109.1
-4.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.10
AUPH's Price-to-Net-Cash is ranked higher than
82% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. AUPH: 3.10 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AUPH' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.19  Med: 5.55 Max: 175
Current: 3.1
2.19
175
Price-to-Net-Current-Asset-Value 3.05
AUPH's Price-to-Net-Current-Asset-Value is ranked higher than
82% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. AUPH: 3.05 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AUPH' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.11  Med: 5.3 Max: 50
Current: 3.05
2.11
50
Price-to-Tangible-Book 3.04
AUPH's Price-to-Tangible-Book is ranked higher than
72% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. AUPH: 3.04 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AUPH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.54  Med: 4.92 Max: 32.08
Current: 3.04
1.54
32.08
Price-to-Intrinsic-Value-Projected-FCF 25.17
AUPH's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
86% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. AUPH: 25.17 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AUPH' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 12.5  Med: 18.67 Max: 25.71
Current: 25.17
12.5
25.71
Price-to-Median-PS-Value 31.79
AUPH's Price-to-Median-PS-Value is ranked lower than
99% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. AUPH: 31.79 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AUPH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 1.08 Max: 65
Current: 31.79
0.04
65
Earnings Yield (Greenblatt) % -11.95
AUPH's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. AUPH: -11.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AUPH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5374.6  Med: -25.8 Max: 28287.3
Current: -11.95
-5374.6
28287.3

More Statistics

Revenue (TTM) (Mil) $0.42
EPS (TTM) $ -1.38
Beta2.59
Short Percentage of Float0.00%
52-Week Range $2.02 - 10.54
Shares Outstanding (Mil)83.49

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 0 0 0 39
EPS ($) -0.68 -0.54 -0.50 -0.12
EPS without NRI ($) -0.68 -0.54 -0.50 -0.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}